Search
ceftobiprole (Zeftera/Zevtera)
FDA-approval pending, March 2010
Indications:
- treatment of complicated skin & skin-structure infections, including diabetic foot infections
- ventilator-associated pneumonia [5]
Dosage: 500 mg IV every 12 hours Antibiotic sensitivity:
- methicillin-resistant Staphylococcus aureus (MRSA) [4]
- penicillin-resistant Streptococcus pneumonia
- Gram-negative bacteria, including Pseudomonas
Adverse effects:
- nausea (14%)
- taste disturbance (8%)
Interactions
drug adverse effects of cephalosporins
General
cephalosporin, 5th generation
References
- Medical Knowledge Self Assessment Program (MKSAP) 15,
American College of Physicians, Philadelphia 2009
- Wikipedia: Ceftobiprole
http://en.wikipedia.org/wiki/Ceftobiprole
- Noel GJ et al
Results of a Double-Blind, Randomized Trial of Ceftobiprole
Treatment of Complicated Skin and Skin Structure Infections
Caused by Gram-Positive Bacteria
Antimicrobial Agents and Chemotherapy, 2008, 52:37-44
PMID: 17954698
http://aac.asm.org/cgi/content/abstract/52/1/37?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=bacteria&searchid=1&FIRSTINDEX=3030&resourcetype=HWFIG
- Vidaillac C, Rybak MJ.
Ceftobiprole: first cephalosporin with activity against
methicillin-resistant Staphylococcus aureus.
Pharmacotherapy. 2009 May;29(5):511-25. Review.
PMID: 19397461
- Rapid Review Quiz: Hospital-Acquired Pneumonia
Medscape. Sept 15, 2022
https://reference.medscape.com/viewarticle/980567